Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF) on LinkedIn:
”Very impressed with all the tech and regulatory advances deployed by the Ministry of Health Saudi Arabia and the leadership of Dr Hatoon Ezzat dedicated to the management of inherited blood disorders in general and thalassemia in specific. Outcomes from such initiatives will surely have global implications on disease understanding and care.”
Quoting Thalassaemia International Federation (TIF)‘s post:
”High-Level TIF–Kingdom of Saudi Arabia Strategic Meeting | 14 December 2025
A high-level delegation of the Thalassaemia International Federation – TIF held a strategic meeting on 14 December 2025 with senior representatives of the Ministry of Health Saudi Arabia, underscoring a shared commitment to accelerating progress in the prevention, control, and comprehensive management of thalassaemia and other haemoglobinopathies.
The TIF delegation comprised Dr. Androulla Eleftheriou, TIF Executive Director; Prof. john porter, Professor of Haematology and Consultant Haematologist at University College London Hospitals (UK); Prof. Khaled Musallam, MD, PhD, Group Chief Research Officer of Burjeel Holdings and Founding Director of CR-RBD (UAE); and Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA, Professor of Cardiology at the National and Kapodistrian University of Athens (Greece), members of TIF’s International Scientific Advisory Board.
The delegates met with H.E. Dr. Mohammed K. Alabdulaali, Assistant Deputy Minister for Hospital Services; Dr. Hatoon Ezzat, Assistant Minister’s Advisor and General Supervisor of Blood Disorders; and Prof. Ahmad Tarawah, Consultant in Pediatric Hematology/Oncology.
During the discussions, TIF congratulated the Government of the KSA on its notable progress in strengthening national systems for the control and management of thalassaemia and other haemoglobinopathies, as well as on the impressive outcomes of its health-sector digitaltransformation.
Particular emphasis was placed on advancing integrated digital health ecosystems and strengthening datasystems, enabling smarter service planning, better follow-up, improved continuity of care, and a more streamlined patientjourney across different levels of the health system.
TIF also commended the KSA’s leadership in facilitating access to healthinnovation, including its distinction as the first country globally to authorise the novel oral therapy PYRUKYND® (mitapivat) for adult patients with transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) α- or β-thalassaemia.
Building on an already excellent and long-standing collaboration between TIF and the KSA, the meeting also explored a forward-looking agenda of joint initiatives.
These include co-developed educational activities and collaborative actions that could support regional and international efforts to improve standards of care and outcomes for patients and their families.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 12:44Sumedha Dash: Inspiring the Next Generation of Voluntary Blood Donors at CV Raman Global University
-
Jun 29, 2026, 12:35Dilini Christina Ranasinghe: Behind Every Unit of Blood
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026